Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population

Journal of Clinical Oncology

Volumn 34, Issue 24, 2016, Pages 2851-2857

  Bower, Hannah ^a   Björkholm, Magnus ^a,b   Dickman, Paul W ^a   Höglund, Martin ^c   Lambert, Paul C ^a,d   Andersson, Therese M L ^a,e  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^d UNIVERSITY OF LEICESTER   (United Kingdom)

^e DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CANCER REGISTRY; CANCER SURVIVAL; CENSORSHIP; CHRONIC MYELOID LEUKEMIA; FEMALE; FOLLOW UP; HUMAN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MIDDLE AGED; PRIORITY JOURNAL; SWEDEN; AGE; ALLOTRANSPLANTATION; EPIDEMIOLOGY; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MORTALITY; STATISTICS AND NUMERICAL DATA; STEM CELL TRANSPLANTATION;

PROTEIN KINASE INHIBITOR;

AGE FACTORS; AGED; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LIFE EXPECTANCY; MIDDLE AGED; PROTEIN KINASE INHIBITORS; STEM CELL TRANSPLANTATION; SWEDEN; TRANSPLANTATION, HOMOLOGOUS;

EID: 84982090948     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.66.2866     Document Type: Article

References (28)

1. Druker BJ: Current treatment approaches for chronic myelogenous leukemia. Cancer J 7:S14-S18, 2001(suppl 1)
2. Wedelin C, Björkholm M, Mellstedt H, et al: Clinical findings and prognostic factors in chronic myeloid leukemias. Acta Med Scand 220:255-260, 1986
3. Höglund M, Sandin F, Hellström K, et al: Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: Report from the population-based Swedish CML registry. Blood 122:1284-1292, 2013
4. Goldman JM: Allogeneic bone marrow transplantation: State of the art and future directions. Bone Marrow Transplant 4:133-134, 1989(suppl 1)
5. O'Brien S, Kantarjian H, Talpaz M: Practical guidelines for the management of chronic myelogenous leukemia with interferon alpha. Leuk Lymphoma 23:247-252, 1996
6. Druker BJ, Sawyers CL, Kantarjian H, et al: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344:1038-1042, 2001
7. O'Brien SG, Guilhot F, Larson RA, et al: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348:994-1004, 2003
8. Björkholm M, Ohm L, Eloranta S, et al: Success story of targeted therapy in chronic myeloid leukemia: A population-based study of patients diagnosed in Sweden from 1973 to 2008. J Clin Oncol 29:2514-2520, 2011
9. Ohm L, Lundqvist A, Dickman P, et al: Realworld cost-effectiveness in chronic myeloid leukemia: The price of success during four decades of development from non-targeted treatment to imatinib. Leuk Lymphoma 56:1385-1391, 2015
10. Andersson TML, Dickman PW, Eloranta S, et al: Estimating the loss in expectation of life due to cancer using flexible parametric survivalmodels. Stat Med 32:5286-5300, 2013
11. Hakama M, Hakulinen T: Estimating the expectation of life in cancer survival studies with incomplete follow-up information. J Chronic Dis 30:585-597, 1977
12. Socialstyrelsen: Cancer Incidence in Sweden 2011. Stockholm, Sweden, Socialstyrelsen, 2012
13. Barlow L, Westergren K, Holmberg L, et al: The completeness of the Swedish Cancer Register: A sample survey for year 1998. Acta Oncol 48:27-33, 2009
14. Dickman PW, Adami HO: Interpreting trends in cancer patient survival. J Intern Med 260:103-117, 2006
15. Ederer F, Axtell LM, Cutler SJ: The relative survival rate: A statistical methodology. Natl Cancer Inst Monogr 6:101-121, 1961
16. Lambert PC, Royston P: Further development of flexible parametric models for survival analysis. Stata J 9:265-290, 2009
17. Lambert PC, Royston P. Flexible Parametric Survival Analysis Using Stata: Beyond the Cox model. College Station, TX, Stata Press, 2011
18. Durrleman S, Simon R: Flexible regression models with cubic splines. Stat Med 8:551-561, 1989
19. Statistics Sweden: Demographics Report: The Future Population of Sweden 2012-2060, Stockholm, Sweden, Statistics Sweden, 2012
20. Duman BB, Paydas S, Disel U, et al: Secondary malignancy after imatinib therapy: Eight cases and review of the literature. Leuk Lymphoma 53:1706-1708, 2012
21. Gunnarsson N, Stenke L, Höglund M, et al: Second malignancies following treatment of chronic myeloid leukaemia in the tyrosine kinase inhibitor era. Br J Haematol 169:683-688, 2015
22. Dahlen T, Edgren G, Hoglund M, et al: increased risk of cardiovascular events associated with TKI treatment in Chronic Phase Chronic Myeloid Leukemia. Data from Swedish population-based registries. Presented at the 56th ASH Annual Meeting and Exposition, San Francisco, CA, December 6-9, 2014
23. Jabbour E, Kantarjian H, Cortes J: Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronicmyeloid leukemia: An evolving treatment paradigm. Clin Lymphoma Myeloma Leuk 15:323-334, 2015
24. Ibrahim AR, Clark RE, Holyoake TL, et al: Second-generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia in whom imatinib therapy has failed. Haematologica 96:1779-1782, 2011
25. Cortes JE, Kim DW, Pinilla-Ibarz J, et al: A phase 2 trial of ponatinib in Philadelphia chromosomepositive leukemias. N Engl J Med 369:1783-1796, 2013
26. Mahon FX, Réa D, Guilhot J, et al: Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: The prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 11:1029-1035, 2010
27. Kantarjian HM, Smith TL, O'Brien S, et al: Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. Ann Intern Med 122:254-261, 1995
28. Sasaki K, Strom SS, O'Brien S, et al: Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: Analysis of patient data from six prospective clinical trials. Lancet Haematol 2:e186-e193, 2015